This page contains a Flash digital edition of a book.
complet“One new and very recently study has been carried out by


ed patient satisfaction


Galderma and was reported briefly at IMCAS, 2012.


”


satisfaction study has been carried out by Galderma and was reported briefly at IMCAS, 2012. The full details of the study (‘ANGEL’) have not yet been published, but the results are real-world and direct from patient information. This was an international multi-centre study,


non-interventional, and carried out in France, the UK, Germany, and Spain. A large population of 551 patients was enrolled, who were questioned 3 weeks and 4 months after treatment with AZZALURE® for glabellar lines. Patients were asked straightforward questions, such as ‘what was your motivation for treatment?’, with a range of multiple choice answers that could be selected. The full data will be published this year but, as an


example, the simple question ‘did the treatment meet your expectations?’ gave the response spectrum shown in Figure 2. In total, at week 3, 93.4% of patients reported that


the treatment either met or surpassed their expectations. This only reduced to


88.7% after


4 months, further supporting the fact that this aesthetic treatment has a long-lasting effect very much liked by the patients. The 10% of patients reporting disappointment after 4 months are likely to be a somewhat critical group who, in many circumstances, have very high expectations that this form of treatment clearly cannot meet.


References


1. Ascher B, Talarico S, Cassuto D et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) - Part I: Upper facial wrinkles. J Eur Acad Dermatol Venereol 2010; 24(11): 1278–84


2. Ascher B, Talarico S, Cassuto D et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) - Part II: Wrinkles on the middle and lower face, neck and chest. J Eur Acad Dermatol Venereol 2010; 24(11):1285–95


3. Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 2004; 114(6 Suppl): 1S–22S


4. Kane M, Donofrio L, Ascher B et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel’s assessment and recommendations. J Drugs Dermatol 2010; 9(1 Suppl): s7–22


5. Pickett A, Caird D. Comparison of type a botulinum toxin products in clinical use. J Clin Pharm Ther 2008; 33(3): 327–8


6. Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol 2010; 9(9): 1085–91


7. Park J, Lee MS, Harrison AR. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol 2011; 5: 725–32


8. Pickett A. Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data. Clin Ophthalmol 2011; 5: 1287–90


9. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011; 57(4): 555–65


10. Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009; 11(2): 77–83


11. Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe


glabellar lines. J Drugs Dermatol 2011; 10(1): 39–44


12. Nestor MS, Ablon GR. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard. J Drugs Dermatol 2011; 10(10): 1148–57


13. Carruthers J, Carruthers A, Monheit GD, Davis PG. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes. Dermatol Surg 2010; 36(Suppl 4): 2135–45


14. de Boulle K, Fagien S, Sommer B, Glogau R. Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 2010; 5: 101–18


15. de Boulle K. Patient satisfaction with different botulinum toxin type


A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther 2008; 10(2): 87–92


16. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142(3): 320–6


17. Rzany B, Ascher B, Monheit G. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. J Eur Acad Dermatol Venereol 2010; 24(Suppl 1): 1–14


18. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow’s feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35(10): 1478–86


19. Ascher B, Zakine B, Kestemont P et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthet Surg J 2005; 25(4): 365–75


20. Fagien S, Carruthers JD. A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures. Plast Reconstr Surg 2008; 122(6): 1915–25


21. Kosowski TR, McCarthy C, Reavey PL et al. A systematic review of patient-reported outcome measures after facial cosmetic surgery and/or nonsurgical facial rejuvenation. Plast Reconstr Surg 2009; 123(6): 1819–27


22. Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Caird D; German– Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33(1 Spec No.): S18–25


23. Pickett A, Rzany B. Botulinum toxin in aesthetic applications: ‘How often misused words generate misleading thoughts’. J Cosmet Laser Ther 2009: 11(3): 178–9


 Acknowledgements The author would like to thank Leonor Vignol of Galderma for access to the ANGEL study data available so far.


 The opinions and comments expressed in this article are those of the author and Toxin Science Limited alone.


These data are fascinating and represent a wide set of patients, giving them significance and strength. We look forward to sharing the full picture.


Conclusions Assessing patient satisfaction is linked to many things. Perhaps this could be described as the most significant modern issue surrounding the use of BoNT aesthetically. However, only through our understanding of the products, what they are, how they work, what their targets are, what their multitude of effects can be — not just relaxation of the muscles, but even properties to directly affect the skin — and, in addition, their science, can we move forward to adapt, tune and refine the treatments for the next years to come.


e“Did the treatment meet your ”


xpectations? In total, at week 3,


93.4% of patients reported that the treatment either met or surpassed their expectations.


prime-journal.com | March 2012


❚


91


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112